{"filings":[{"id":93388,"accession_number":"0001193125-26-210369","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus Q1 revenue $377.3M (+1.2% YoY); GAAP EPS $1.80, adjusted EPS $1.46","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $377.3M (+1.2%); GAAP diluted EPS $1.80 (+76.5%), adjusted diluted EPS $1.46 (-4.6%).","PYLARIFY sales $240.9M (-6.5% YoY); DEFINITY $84.6M (+6.8%); Neuraceq $35.4M.","FDA approved PYLARIFY TruVu (new formulation); phased launch begins Q4 2026.","FDA tentative approval for PNT2003 (Lutetium Lu 177 Dotatate radioequivalent for GEP-NETs); launch pending.","Reaffirmed FY2026 guidance: revenue $1.4B-$1.45B, adjusted EPS $5.00-$5.25."],"consensus_eps_estimate":null,"consensus_eps_actual":1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":377333000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93387,"accession_number":"0001193125-26-201556","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Lantheus shareholders approve board declassification and amended equity plan with 2M additional shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certificate of Amendment filed to declassify Board of Directors over three years; removal with/without cause after declassification.","Shareholders approved Amended & Restated 2026 Equity Incentive Plan, increasing share reserve by 2.0M shares.","Non-employee director compensation limit changed: $1.25M in first year, $750k in subsequent years.","Say-on-pay frequency set to annual after advisory vote; all director nominees elected.","Deloitte & Touche ratified as independent auditor for fiscal year ending Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104958,"accession_number":"0001193125-26-073439","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus Q4 revenue $406.8M, adj EPS $1.67; narrows focus to PET radiodiagnostics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $406.8M (+4% YoY); FY2025 revenue $1.54B; GAAP diluted EPS $0.82 Q4, $3.41 FY.","Adjusted diluted EPS $1.67 Q4 (+4.7% YoY), $6.08 FY; PYLARIFY sales $240.2M (-9.7%).","Company sharpens focus on innovative PET radiodiagnostics; pursuing alternatives for radiotherapeutic assets; completed SPECT divestiture to SHINE.","FY2026 guidance: revenue $1.4B-$1.45B, adjusted diluted EPS $5.00-$5.25.","Repurchased $100M of stock in Q4; cash and equivalents $359.1M after acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":3.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":1541609000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121215,"accession_number":"0001193125-25-277754","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lantheus CEO Brian Markison to retire Dec 31, 2025; consulting deal through Mar 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Brian Markison retiring effective Dec 31, 2025; enters consulting agreement from Jan 1 to Mar 31, 2026.","Monthly advisory fee of $83,333 during consulting period, subject to restrictive covenants.","Base salary paid through retirement; 2025 annual bonus paid lump sum within 60 days if earned.","Outstanding equity awards vest through retirement date, then follow retirement provisions.","No successor named; consulting period extendable by mutual agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121214,"accession_number":"0001193125-25-268103","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Lantheus Q3 revenue $384M (+1.4% YoY), adj. EPS $1.27; CEO Markison to retire, Heino interim CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $27.8M ($0.41 fully diluted EPS); adjusted EPS $1.27, down 25.3% YoY.","PYLARIFY sales $240.6M (-7.4% YoY); DEFINITY $81.8M (+6.3%). Free cash flow $94.7M.","CEO Brian Markison retires Dec 31, 2025; President Paul Blanchfield leaves Nov 7.","Mary Anne Heino appointed Executive Chair Nov 7, to serve as Interim CEO from Jan 1, 2026.","FY2025 guidance: revenue $1.49B–$1.51B; adj. EPS $5.50–$5.65; $100M share repurchase in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":2.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":1134823000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137861,"accession_number":"0001193125-25-178046","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lantheus CCO Amanda Morgan takes personal leave effective Aug. 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Commercial Officer Amanda Morgan on personal leave starting August 8, 2025.","Company did not disclose leave duration or interim replacement.","No business impact or further leadership changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137860,"accession_number":"0000950170-25-103543","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Lantheus Q2 rev $378M, adj EPS $1.57; cuts FY25 guidance; FDA NDA acceptance; $400M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $378.0M (-4.1% YoY); GAAP EPS $1.12; adjusted EPS $1.57.","PYLARIFY sales $250.6M (-8.3%); DEFINITY sales $83.9M (+7.5%).","FY25 revenue guidance cut to $1.475-$1.51B from $1.55-$1.585B; adj EPS to $5.50-$5.70 from $6.60-$6.70.","FDA accepted NDA for new piflufolastat F 18 formulation; PDUFA date March 6, 2026; batch size +~50%.","Board authorized $400M share repurchase program through Dec 2027, replacing prior $400M program."],"consensus_eps_estimate":null,"consensus_eps_actual":2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":750809000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137859,"accession_number":"0001193125-25-162233","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.","Appointed Dr. Ludger Dinkelborg, former Life Molecular CEO, as Head of R&D effective Aug 1, 2025.","Transaction adds commercial infrastructure, R&D capabilities, and international footprint for Alzheimer's radiodiagnostics.","Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155241,"accession_number":"0001628280-25-022871","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus Q1 adj EPS $1.53 (-9.5% YoY); cuts FY25 adj EPS guidance to $6.60-$6.70 from $7.00-$7.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $372.8M (+0.8% YoY); GAAP EPS $1.02 vs $1.87; adj EPS $1.53 vs $1.69.","PYLARIFY sales $257.7M (-0.5%); DEFINITY $79.2M (+3.5%).","FY2025 revenue guidance narrowed to $1.550B-$1.585B; adj EPS guidance lowered to $6.60-$6.70 from $7.00-$7.20.","Closed Evergreen Theragnostics; agreed to acquire Life Molecular Imaging (Q2); announced SPECT divestiture to SHINE (by year-end).","MK-6240 met endpoints in pivotal studies; NDA planned Q3 2025. PNT2002 will not proceed to NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":372764000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155240,"accession_number":"0001193125-25-112812","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Lantheus stockholders elect four Class I directors and approve board declassification proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four nominees elected: Mary Anne Heino (54.3M for), Dr. Gérard Ber (57.2M for), Julie Eastland (56.1M for), Samuel Leno (41.5M for).","Advisory say-on-pay approved with 57.8M for, 2.8M against; Deloitte ratified as auditor with 64.2M for.","Stockholder proposal to declassify board approved on advisory basis: 59.3M for, 0.7M against.","Bylaws amended to add procedural requirements for special meetings and update director nomination/proxy access rules.","Board size automatically reduces upon vacancy to conform to amended Delaware General Corporation Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155239,"accession_number":"0001193125-25-069927","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Lantheus closes $275M acquisition of Evergreen Theragnostics; adds OCTEVY and CDMO capabilities","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed acquisition of Evergreen Theragnostics for $275M cash upfront ($250M + $25M milestone achieved pre-close).","Additional contingent milestone payments up to $727.5M remain payable under the Merger Agreement.","Acquisition adds OCTEVY, a registrational-stage PET imaging agent for neuroendocrine tumors.","Adds Evergreen's radioligand therapy manufacturing infrastructure and revenue-generating CDMO business.","CEO Brian Markison: acquisition enhances capabilities across the radiopharmaceutical value chain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173757,"accession_number":"0001628280-25-007965","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus Q4 revenue $391M (+10.5%); GAAP EPS $(0.17), adj. EPS $1.59; FY25 guide $1.55B-$1.61B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $391.1M (+10.5% YoY); PYLARIFY $266M (+15.7%), DEFINITY $86.2M (+17.9%).","GAAP fully diluted EPS $(0.17) vs $1.47 prior; adj. EPS $1.59 (-9% YoY).","Agreements to acquire Life Molecular (Alzheimer's radiodiagnostic) and Evergreen Theragnostics (manufacturing), expected H2 2025.","CMS final 2025 OPPS rule grants separate payment for PYLARIFY and other diagnostic radiopharmaceuticals.","FY 2025 revenue guidance $1.545B-$1.610B; adjusted EPS guidance $7.00-$7.20."],"consensus_eps_estimate":null,"consensus_eps_actual":4.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1533910000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173756,"accession_number":"0001193125-25-016381","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lantheus appoints Dr. Phuong Khanh Morrow to board, effective Feb 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Phuong Khanh Morrow appointed independent director effective Feb 1, 2025; board expands to 11.","Morrow is Head of Oncology TAU at Takeda, former CMO at CRISPR Therapeutics, and VP at Amgen.","Will receive $60k annual cash retainer, $7.5k STC fee, initial $100k equity grant (50% RSU, 50% options), and $400k annual equity.","Appointed to Science and Technology Committee; board now has 11 directors, 9 independent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173755,"accession_number":"0001193125-25-013841","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Lantheus to acquire Evergreen Theragnostics for $250M upfront plus up to $752.5M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash consideration $250M; potential milestone payments up to $752.5M based on OCTEVY and pipeline products.","Evergreen adds radiopharmaceutical CDMO manufacturing infrastructure and registrational-stage NET diagnostic OCTEVY.","Transaction expected to close in second half of 2025, subject to regulatory clearances and customary conditions.","Lantheus reaffirms FY2024 revenue guidance of $1.51B-$1.52B and adjusted EPS of $6.65-$6.70."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173754,"accession_number":"0001193125-25-004904","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lantheus to Acquire Life Molecular Imaging for $350M Upfront with Potential $400M Earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $350M for Life Molecular Imaging, with up to $400M in potential earnout and milestone payments.","Acquisition adds Neuraceq (florbetaben F18), an FDA-approved PET imaging agent for Alzheimer's disease diagnosis.","Lantheus will assume up to $30M in seller's retained contingent liabilities under certain contractual arrangements.","Transaction expected to close in H2 2025, subject to Life Healthcare shareholder vote, antitrust clearances, and SA Reserve Bank approval.","Lantheus expects the deal to be accretive to adjusted EPS within 12 months of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190737,"accession_number":"0001193125-24-284219","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Lantheus expands revolving credit facility to $750M, extends maturity to Dec 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving line increased from $350M to $750M; can request another $350M.","Maturity extended from Dec 2027 to Dec 2029.","Interest rate margin ranges reduced; unused commitment fee cap cut to 0.30%.","New lenders added: Citibank, Mizuho, PNC, TD Bank.","Amendment effective Dec 19, 2024; closed with existing agent Citizens Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190736,"accession_number":"0001193125-24-282047","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Lantheus CMO Jeff Humphrey to depart Jan 3, 2025; search underway for replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Humphrey, MD, resigns as Chief Medical Officer; last day January 3, 2025.","Departure not due to disagreement with company or board on operations, clinical programs, or policies.","CEO Brian Markison and President Paul Blanchfield assume interim leadership of R&D.","Company has initiated a search for a new Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190735,"accession_number":"0001193125-24-262071","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lantheus authorizes $250M share repurchase program over next 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $250M in common stock repurchases within one year.","Repurchases may be via open market, private transactions, or other means at management's discretion.","Company may adopt 10b5-1 trading plans to facilitate repurchases.","CEO cites strong financial position and commitment to shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190734,"accession_number":"0001628280-24-045456","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus Q3 revenue up 18.4% to $378.7M; adjusted EPS $1.70 beats prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $131.1M ($1.79 diluted EPS) vs $132.0M ($1.88) in Q3 2023.","PYLARIFY sales $259.8M (+20.6%); DEFINITY sales $77.0M (+14.3%).","Acquired NAV-4694, a Phase 3 beta-amyloid imaging agent; NDA planned for 2026.","CMS CY2025 final rule improves separate payment for diagnostic radiopharmaceuticals including PYLARIFY, effective Jan 1, 2025.","FY2024 guidance narrowed: revenue $1.51B-$1.52B; adj. EPS $6.65-$6.70, at higher end of prior range."],"consensus_eps_estimate":null,"consensus_eps_actual":4.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":1142800000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207215,"accession_number":"0001193125-24-226113","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Lantheus to release SPLASH trial data in Oct 2024 after 75% OS events reached","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to release Phase 3 SPLASH data in October 2024 for 177Lu-PNT2002 in PSMA-expressing mCRPC.","Release triggered by reaching 75% of protocol-specified target overall survival events.","Trial randomized 412 patients 2:1; 84.6% of control arm crossed over to PNT2002.","Primary endpoint is radiographic progression-free survival; 80% of patients from North America."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207214,"accession_number":"0001193125-24-213726","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lantheus appoints Julie Eastland to Board of Directors, effective Sept 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to ten directors; Eastland is a Class I director and Audit Committee member.","Eastland qualifies as independent under Nasdaq rules; compensation includes $60K/yr cash plus prorated equity grant valued at $266,666.67.","She brings biotech and finance experience, most recently CEO of Harpoon Therapeutics until its acquisition by Merck in March 2024.","No arrangements or family relationships with existing directors or officers; no disclosable transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207213,"accession_number":"0001628280-24-033629","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus Q2 revenue up 22.5% to $394.1M, adjusted EPS $1.80; lowers FY 2024 adjusted EPS guidance to $6.60-$6.70","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $394.1M (+22.5% YoY), driven by PYLARIFY sales $273.3M (+29.8%) and DEFINITY $78.1M (+10.7%).","GAAP diluted EPS $0.88 (vs $1.33); adjusted diluted EPS $1.80 (vs $1.54), +16.4%.","Acquired NAV-4694 (Alzheimer's), global rights to RM2 theranostic pair (prostate/breast), and two preclinical assets from Radiopharm Theranostics.","FY 2024 revenue guidance reaffirmed $1.50-1.52B; adjusted EPS guidance lowered to $6.60-6.70 from $7.00-7.20 due to BD investments.","CMS proposed OPPS rule improves separate payment for diagnostic radiopharmaceuticals like PYLARIFY in hospital outpatient setting."],"consensus_eps_estimate":null,"consensus_eps_actual":2.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":764066000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224581,"accession_number":"0001193125-24-169713","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantheus acquires global rights to Life Molecular's GRPR-targeting radiotheranostic pair for $35M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment $35M plus regulatory milestone payments and royalties.","Pair includes 177Lu-DOTA-RM2 (therapeutic) and 68Ga-DOTA-RM2 (diagnostic) targeting GRPR in prostate, breast, and other cancers.","Lantheus plans Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer in 2025; 68Ga-DOTA-RM2 as companion diagnostic.","Strengthens Lantheus' prostate cancer portfolio and expands pipeline to include breast cancer.","Life Molecular will complete ongoing Phase 1/2a dose escalation study in collaboration with Lantheus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.68,"calibrated_materiality_score":0.68,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224580,"accession_number":"0001193125-24-167026","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lantheus appoints Kimberly Brown as Chief Accounting Officer effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brown joins from Repligen (VP Controller); Andrea Sabens transitions to new role as of August 1.","Annual base salary $350K, target bonus 35% of base, $50K sign-on bonus.","Initial equity award of $900K: 50% RSUs, 50% NSOs, vesting over three years.","Eligible for 2025 discretionary annual equity target of $450K.","Brown is a CPA, formerly at Grant Thornton, with global controllership and M&A experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224579,"accession_number":"0001193125-24-139440","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lantheus appoints new CMO and CSO; Humphrey and Provost roles change May 28","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer, both effective May 28, 2024.","Humphrey brings 30+ years clinical oncology experience from Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer.","Provost transitions from CMO to CSO to lead business development and pipeline acceleration; holds medicine degree from Sorbonne University.","CEO Markison says moves will 'enable our team to accelerate innovation' in radiopharmaceutical diagnostics and therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224578,"accession_number":"0001628280-24-019794","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus Q1 revenue $370M (+23% YoY), EPS $1.87; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $370M (+23% YoY); PYLARIFY sales $258.9M (+32.4%), DEFINITY $76.6M (+11.2%)","GAAP diluted EPS $1.87 (vs -$0.04 YoY); adjusted diluted EPS $1.69 (vs $1.47 YoY)","FY2024 revenue guidance raised to $1.50-1.52B (prior $1.41-1.445B); adj. EPS to $7.00-7.20 (prior $6.50-6.70)","Q2 FY2024 guidance: revenue $380-390M, adj. diluted EPS $1.81-1.86","CEO change: Brian Markison appointed effective March 1; MaryAnne Heino becomes Chair; Phase 3 SPLASH PNT2002 met primary endpoint"],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":369975000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224577,"accession_number":"0001193125-24-122683","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Lantheus shareholders approve 4M share equity plan increase; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment increasing share reserve under 2015 Equity Incentive Plan by 4,000,000 to 14,930,277.","Class III directors elected: Markison (55.1M for), Pruden (53.3M for), Thrall (38.0M for, 20.0M against).","Advisory say-on-pay compensation vote passed: 56.6M for, 1.3M against.","Deloitte & Touche ratified as independent auditor for fiscal 2024 with 62.4M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243875,"accession_number":"0001628280-24-006157","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus Q4 2023 rev $354M (+34.5%), adj EPS $1.75; FY2024 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $354M (+34.5% YoY), including $15M RELISTOR milestone; FY2023 revenue $1.3B (+38.6% YoY).","GAAP net income Q4 $103.4M ($1.47) vs loss of $119.2M (-$1.74) in Q4 2022; FY net income $326.7M ($4.65).","Adjusted diluted EPS Q4 $1.75 (+28% YoY); FY2023 $6.23 (+47.7% YoY).","FY2024 guidance: revenue $1.41-1.445B, adjusted EPS $6.50-6.70 (above FY2023 $6.23).","Free cash flow FY2023 $258.7M; net cash from ops $305.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":4.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1296429000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243874,"accession_number":"0001193125-24-016143","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Lantheus confirms patent infringement lawsuit by Novartis over generic Lutetium Lu 177 Dotatate ANDA","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Lawsuit filed by Advanced Accelerator Applications (Novartis entities) in U.S. District Court for Delaware against Lantheus and its subsidiary.","Suit stems from Lantheus's ANDA No. 217060 for generic version of LUTATHERA (lutetium Lu 177 dotatate) for GEP-NETs.","Lantheus believes it is the 'first applicant' and eligible for 180 days of generic marketing exclusivity in the U.S.","No financial impact or settlement terms disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243873,"accession_number":"0001193125-24-012605","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lantheus CEO Heino retires March 1; Markison named CEO; FY23 revenue $1.295-1.297B, up 38-39%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Anne Heino to retire as CEO effective March 1, 2024; becomes Chair of the Board.","Brian Markison, current Board Chair, to become CEO effective March 1, 2024; serves as Executive Chairman until then.","Julie McHugh appointed Lead Independent Director effective immediately.","Markison employment agreement: $950k base salary, 100% target bonus, $8.5M equity award (50% RSU, 50% PSU).","Preliminary FY2023 revenue expected $1.295-1.297B, up 38-39% YoY, exceeding prior guidance of $1.255-1.270B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243872,"accession_number":"0001628280-24-000888","cik":1521036,"company_name":"Lantheus Holdings, Inc.","ticker":"LNTH","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantheus pre-announces FY2023 revenue ~$1.296B, beating guidance; PYLARIFY up 62%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue expected $1.295-1.297B, up 38-39% YoY, above prior guidance of $1.255-1.270B.","PYLARIFY revenue $851-853M (+61-62% YoY); DEFINITY ~$279M (+14%); includes $15M RELISTOR milestone.","Company cites over 6 million patients impacted and strong radiopharmaceutical platform momentum.","Full FY2023 results and 2024 financial expectations to be released in late February 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":4.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1296429000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6529488432.037541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}